Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. operates commercially as Helus Pharma and reports developments as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists for depression, anxiety, and other mental health conditions. Company updates commonly address HLP003 in major depressive disorder, HLP004 in generalized anxiety disorder, investigational 5-HT receptor-focused compounds, clinical-research collaborations, regulatory-policy commentary, and scientific or medical leadership additions.
News about the company also covers public-company finance and corporate structure, including common-share offerings, pre-funded warrants, at-the-market equity programs, exchange-listing changes, conference presentations, quarterly financial results, and governance transitions tied to its development-stage pharmaceutical operations.
Cybin Inc. (AMEX:CYBN) announced participation by CEO Doug Drysdale in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 8:40 a.m. ET. The event will highlight the company’s focus on transforming psychedelics into therapeutics for mental health issues. A webcast will be available for those interested in listening to the discussion. Cybin, operational in Canada, the US, UK, and Ireland, is committed to the development of innovative therapeutic solutions leveraging proprietary drug discovery platforms.
Cybin announced that its subsidiary, Adelia Therapeutics, has reached a milestone under a December 4, 2020, agreement, resulting in the issuance of 17,239.5 Class B shares. This issuance satisfies approximately CAD $233,424 due to Adelia's shareholders, priced at CAD $13.54 per share. The shares are exchangeable for Cybin shares on a 10:1 basis, with specific timelines for exchange eligibility extending to 2023. Cybin focuses on advancing psychedelics for therapeutic uses, aiming to address mental health issues.
Cybin, a biopharmaceutical company focused on advancing "Psychedelics to Therapeutics™", will have its CEO Doug Drysdale participate in a fireside chat at the Aegis Virtual Conference on February 24, 2022, at 2:00 p.m. ET. The conference runs from February 23 to February 25, 2022. Interested viewers can access the event through a provided link, with an archived webcast available later on Cybin's investor relations site. Founded in 2019 and headquartered in Canada, Cybin aims to create safe therapeutics for mental health issues.
Cybin announced significant advancements in its clinical programs during Q3 2021, focusing on psychedelic therapies for mental health. The company is preparing for a Phase 1/2a trial of CYB003 targeting major depressive disorder and alcohol use disorder, following a supportive meeting with the UK MHRA. Financially, it reported C$63.6 million in cash, with a Q3 net loss of C$17.2 million. Cybin continues to build its intellectual property portfolio, including a recent U.S. patent for CYB004.
Cybin Inc. has received a crucial composition of matter patent for its investigational deuterated DMT compound, CYB004, from the U.S. Patent and Trademark Office. This patent, expiring in 2041, reinforces the company’s intellectual property in psychedelics and protects CYB004 as a new chemical entity. Preclinical studies show that CYB004 could alleviate negative experiences linked to classical DMT while boosting therapeutic effects. The company plans to submit a clinical trial application for a pilot study of CYB004 in mid-2022, with hopes for significant advancements in treating anxiety disorders.
Cybin Inc. has announced that its subsidiary, Adelia Therapeutics, has achieved key milestones as per a December 2020 contribution agreement. This entitles Adelia's shareholders to receive approximately $551,171.99 CAD (about $437,229.88 USD) in Class B shares, exchangeable into common shares of Cybin on a 10:1 basis. This exchange process will be phased, allowing 33.33% of shares to be exchanged by December 2022, 66.67% by December 2023, and 100% thereafter. Cybin is focused on developing psychedelic-based therapies to address mental health issues.
Cybin Inc. (AMEX:CYBN) will report its third-quarter financial results for the period ending December 31, 2021, on February 10, 2022. A conference call will take place at 8:30 a.m. (EST) on the same day, featuring CEO Doug Drysdale and the management team, who will discuss the results and answer questions. Cybin is focused on developing safe and effective therapeutics for mental health issues, leveraging partnerships with leading scientists and proprietary drug discovery platforms. Investors can access a webcast of the call.
Cybin announced approval from an Institutional Review Board for a feasibility study using Kernel's neuroimaging technology to assess ketamine's psychedelic effects on brain activity. This study, authorized by the FDA in October 2021, aims to provide quantitative data on brain activity related to psychedelics, enhancing understanding and potential treatment options for mental health disorders. Enrollment is expected to start in early 2022. Cybin will retain exclusive rights to innovations discovered through this study, aligning with its goal to advance psychedelics to therapeutics.
Cybin Inc. (NYSE AMERICAN:CYBN) has announced that its subsidiary, Adelia Therapeutics Inc., has achieved a milestone under a contribution agreement dated December 4, 2020. As a result, 15,611.4 Class B common shares will be issued to Adelia shareholders, fulfilling a payment obligation of approximately $235,528.90 (CAD). The effective issue price is about $15.09 per Class B Share, which can be exchanged for Cybin Shares at a ratio of 10:1. This strategic move indicates Cybin's commitment to advancing its psychedelic pharmaceutical therapies.
Cybin Inc. (NYSE American:CYBN) provided a year-end summary highlighting significant milestones achieved in 2021. The company expanded its workforce from 5 to over 55 employees globally and partnered with nearly 50 organizations, conducting over 90 preclinical studies. Major achievements included FDA approvals for clinical trials, promising data for CYB003 and CYB004, and a successful capital raise of $70M, totaling over $120M since inception. Cybin aims to initiate four first-in-human clinical studies in 2022, focusing on mental health treatments.